IDH2 and central nervous system cancer: With the fifth edition of the WHO classification of Tumours of the Central Nervous System (CNS), presence of homozygous CDKN2A/B deletions mandates a CNS WHO grade 4 designation of IDH-mutant astrocytoma independent of histological features.